Skip to content
Study details
Enrolling now

Feasibility/Acceptability of Attentional-Control Training in Survivors

Children's National Research Institute
NCT IDNCT05528939ClinicalTrials.gov data as of Apr 2026
Target enrollment

50

Study length

about 2.2 years

Ages

8–16

Locations

1 site in DC

About this study

Researchers are testing whether a treatment called EndeavorRx can help children who have finished cancer or brain tumor treatment improve their attention. The trial will involve comparing EndeavorRx to a control video game, and it aims to see if the treatment is feasible and acceptable for these young people.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Control video game
  • 2.Use EndeavorRx

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low4%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Endpoints

Secondary: Change from baseline executive functioning assessed by the Behavior Rating Inventory of Executive Functioning, Second Edition (BRIEF-2) Cognitive Regulation Index (CRI) at end of training, Change from baseline inattention assessed by Omission Errors on the Conners' Continuous Performance Test, 3rd Edition (CPT-3) at 4-month follow-up (16 weeks post-training/control +/- 4 weeks), Change from baseline inattention assessed by Omission Errors on the Conners' Continuous Performance Test, 3rd Edition (CPT-3) at end of training, Change from baseline inattention assessed by the ADHD Rating Scale, Fifth Edition (ADHD-RS-5) Inattention subscale at 4-month follow-up (16 weeks post-training/control +/- 4 weeks), Change from baseline inattention assessed by the ADHD Rating Scale, Fifth Edition (ADHD-RS-5) Inattention subscale at end of training, Change from baseline inhibitory control assessed by the Behavior Rating Inventory of Executive Functioning, Second Edition (BRIEF-2) Inhibit subscale at 4-month follow-up (16 weeks post-training/control +/- 4 weeks), Change from baseline inhibitory control assessed by the Behavior Rating Inventory of Executive Functioning, Second Edition (BRIEF-2) Inhibit subscale at end of training

Body systems

Oncology